Cystatins 9 and C as a novel immunotherapy treatment that protects against multidrug-resistant New Delhi metallo-beta-lactamase-1-producing klebsiella pneumoniae

Antimicrobial Agents and Chemotherapy

Volumn 62, Issue 3, 2018, Pages

  Holloway, Alex J ^a   Yu, JiehJuen ^b   Arulanandam, Bernard P ^b   Hoskinson, Sarah M ^a   Eaves Pyles, Tonyia ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

Antimicrobial; Cystatin 9; Cystatin C; Immunomodulation; Immunotherapy; Inflammation; Multidrug resistant; New Delhi metallo beta lactamase 1 producing K. pneumoniae; Pneumonia

Indexed keywords

ANTIINFECTIVE AGENT; COLISTIN; CYSTATIN; CYSTATIN 9; CYSTATIN C; UNCLASSIFIED DRUG; BETA LACTAMASE; BETA-LACTAMASE NDM-1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; APOPTOSIS; ARTICLE; BACTERIAL LOAD; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFICACY; FEMALE; IMMUNOTHERAPY; IN VITRO STUDY; INFLAMMATORY CELL; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; LIPID PEROXIDATION; METALLO BETA LACTAMASE 1 PRODUCING KLEBSIELLA PNEUMONIAE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECT; HUMAN; KLEBSIELLA INFECTION; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOGENICITY; PROCEDURES;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CYSTATIN C; CYSTATINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HUMANS; IMMUNOTHERAPY; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS;

EID: 85042416881     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01900-17     Document Type: Article

References (42)

1. Loffek S, Schilling O, Franzke CW. 2011. Series “matrix metalloproteinases in lung health and disease”: biological role of matrix metalloproteinases: a critical balance. Eur Respir J 38:191–208. https://doi.org/10.1183/09031936.00146510.
2. Zavasnik-Bergant T. 2008. Cystatin protease inhibitors and immune functions. Front Biosci 13:4625–4637. https://doi.org/10.2741/3028.
3. Ochieng J, Chaudhuri G. 2010. Cystatin superfamily. J Health Care Poor Underserved 21:51–70. https://doi.org/10.1353/hpu.0.0257.
4. Bobek LA, Levine MJ. 1992. Cystatins—inhibitors of cysteine proteinases. Crit Rev Oral Biol Med 3:307–332. https://doi.org/10.1177/10454411920030040101.
5. Kopitar-Jerala N. 2006. The role of cystatins in cells of the immune system. FEBS Lett 580:6295–6301. https://doi.org/10.1016/j.febslet.2006.10.055.
6. Poteryaeva ON, Falameyeva OV, Korolenko TA, Kaledin VI, Djanayeva SJ, Nowicky JW, Sandula J. 2000. Cysteine proteinase inhibitor level in tumor and normal tissues in control and cured mice. Drugs Exp Clin Res 26:301–306.
7. Vray B, Hartmann S, Hoebeke J. 2002. Immunomodulatory properties of cystatins. Cell Mol Life Sci 59:1503–1512. https://doi.org/10.1007/s00018-002-8525-4.
8. Gauthier S, Kaur G, Mi W, Tizon B, Levy E. 2011. Protective mechanisms by cystatin C in neurodegenerative diseases. Front Biosci (Schol Ed) 3:541–554.
9. Kaeser S, Herzig M, Coomaraswamy J, Kilger E, Selenica M, Winkler D, Staufenbiel M, Levy E, Grubb A, Jucker M. 2007. Cystatin C modulates cerebral -amyloidosis. Nat Genet 39:1437–1439. https://doi.org/10.1038/ng.2007.23.
10. Kaur G, Levy E. 2012. Cystatin C in Alzheimer’s disease. Front Mol Neurosci 5:79. https://doi.org/10.3389/fnmol.2012.00079.
11. Ervin H, Cox JL. 2005. Late stage inhibition of hematogenous melanoma metastasis by cystatin C over-expression. Cancer Cell Int 5:14. https://doi.org/10.1186/1475-2867-5-14.
12. Tian M, Schiemann WP. 2009. Preclinical efficacy of cystatin C to target the oncogenic activity of transforming growth factor in breast cancer. Transl Oncol 2:174–183. https://doi.org/10.1593/tlo.09145.
13. Magister Š, Kos J. 2013. Cystatins in immune system. J Cancer 4:45–56. https://doi.org/10.7150/jca.5044.
14. Rivera LE, Colón K, Cantres-Rosario YM, Zenón FM, Meléndez LM. 2014. Macrophage derived cystatin B/cathepsin B in HIV replication and neuropathogenesis. Curr HIV Res 12:111–120. https://doi.org/10.2174/1570162X12666140526120249.
15. Eaves-Pyles T, Patel J, Arigi E, Cong Y, Cao A, Garg N, Dhiman M, Pyles RB, Arulanandam B, Miller AL, Popov VL, Soong L, Carlsen ED, Coletta C, Szabo C, Almeida IC. 2013. Immunomodulatory and antibacterial effects of cystatin 9 against Francisella tularensis. Mol Med 19:263–275. https://doi.org/10.1007/s00894-012-1544-7.
16. Khalil MAF, Elgaml A, El-Mowafy M. 2017. Emergence of multidrug-resistant New Delhi metallo--lactamase-1-producing Klebsiella pneumoniae in Egypt. Microb Drug Resist 23:480–487. https://doi.org/10.1089/mdr.2016.0003.
17. Khan AU, Maryam L, Zarrilli R. 2017. Structure, genetics and worldwide spread of New Delhi metallo--lactamase (NDM): a threat to public health. BMC Microbiol 17:101. https://doi.org/10.1186/s12866-017-1012-8.
18. Halaby T, Reuland AE, Naiemi N, Potron A, Savelkoul PH, Vanenbrouke-Grauls CM, Nordmann P. 2012. A case of New Delhi metallo--lactamase 1 (NDM-1)-producing Klebsiella pneumoniae with putative secondary transmission from the Balkan Region in the Netherlands. Antimicrob Agents Chemother 56:2790–2791. https://doi.org/10.1128/AAC.00111-12.
19. Pesesky MW, Hussain T, Wallace M, Wang B, Andleeb S, Burnham CD, Dantas G. 2015. KPC and NDM-1 genes in related Enterobacteriaceae strains and plasmids from Pakistan and the United States. J Emerg Infect Dis 21:1034–1037. https://doi.org/10.3201/eid2106.141504.
20. Barantsevich EP, Churkina IV, Barantsevich NE, Pelkonen J, Schlyakhto EV, Woodford N. 2013. Emergence of Klebsiella pneumoniae producing NDM-1 carbapenemase in Saint Petersburg, Russia. J Antimicrob Chemother 68:1204–1206. https://doi.org/10.1093/jac/dks503.
21. Bosch T, Lutgens SPM, Hermans MHA, Wever PC, Schneeberger PM, Renders NHM, Leenders ACAP, Kluytmans JAJW, Schoffelen A, Noter-mans D, Witteveen S, Bathoorn E, Schouls LM. 2017. Outbreak of NDM-1-producing Klebsiella pneumoniae in a Dutch hospital, with interspecies transfer of the resistance plasmid and unexpected occurrence in unrelated health care centers. J Clin Microbiol 55:2380 –2390. https://doi.org/10.1128/JCM.00535-17.
22. Li JJ, Munoz-Price LS, Spychala CN, DePascale D, Doi Y. 2016. New Delhi metallo--lactamase-1-producing Klebsiella pneumoniae, Florida, USA. Emerg Infect Dis 22:744–746. https://doi.org/10.3201/eid2204.151176.
23. Lee C-R, Lee JH, Park KS, Kim YB, Jeong BC, Lee SH. 2016. Global dissemination of carbapenemase-producing Klebsiella pneumoniae: epidemiology, genetic context, treatment options, and detection methods. Front Microbiol 7:895. https://doi.org/10.3389/fmicb.2016.00895.
24. Pitout JD, Nordmann P, Poirel L. 2015. Carbapenemase-producing Klebsiella pneumoniae, a key pathogen set for global nosocomial dominance. Antimicrob Agents Chemother 59:5873–5884. https://doi.org/10.1128/AAC.01019-15.
25. Hudson CM, Bent ZW, Meagher RJ, Williams KP. 2014. Resistance determinants and mobile genetic elements of an NDM-1-encoding Klebsiella pneumoniae strain. PLoS One 9:e99209. https://doi.org/10.1371/journal.pone.0099209.
26. Robilotti E, Deresinski S. 2014. Carbapenemase-producing Klebsiella pneumoniae. F1000Prime Rep 6:80. https://doi.org/10.12703/P6-80.
27. Liang Z, Li L, Wang Y, Chen L, Kong X, Hong Y, Lan L, Zheng M, Guang-Yang C, Liu H, Shen X, Lou C, Li K, Chen K, Jiang H. 2011. Molecular basis of NDM-1, a new antibiotic resistance determinant. PLoS One 6:e23606. https://doi.org/10.1371/journal.pone.0023606.
28. Zmarlicka MT, Nailor MD, Nicolau DP. 2015. Impact of the New Delhi metallo-beta-lactamase on beta-lactam antibiotics. Infect Drug Resist 8:297–309. https://doi.org/10.2147/IDR.S39186.
29. Zhu K, Lu J, Liang Z, Kong X, Ye F, Jin L, Geng H, Chen Y, Zheng M, Jiang H, Li JQ, Luo C. 2013. A quantum mechanics/molecular mechanics study on the hydrolysis mechanism of New Delhi metallo--lactamase-1. J Comput Aided Mol Des 27:247–256. https://doi.org/10.1007/s10822-012-9630-6.
30. Bauer TT, Ewig S, Rodloff AC, Muller E. 2006. Acute respiratory distress syndrome and pneumonia: a comprehensive review of clinical data. Clin Infect Dis 43:748–756. https://doi.org/10.1086/506430.
31. Okamoto T, Akuta T, Tamura F, van Der Vliet A, Akaike T. 2004. Molecular mechanism for activation and regulation of matrix metalloproteinases during bacterial infections and respiratory inflammation. Biol Chem 385:997–1006. https://doi.org/10.1515/BC.2004.130.
32. Hickman-Davis JM, O’Reilly P, Davis IC, Peti-Peterdi Davis G, Young R, Devlin RB, Matalon S. 2002. Killing of Klebsiella pneumoniae by human alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 282: L944–L956. https://doi.org/10.1152/ajplung.00216.2001.
33. Docobo-érez F, Nordmann P, Domínguez-Herrera J, López-Rojas R, Smani Y, Poirel L, Pachón J. 2012. Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of Klebsiella pneumoniae and Escherichia coli. Int J Antimicrob Agents 39: 251–254. https://doi.org/10.1016/j.ijantimicag.2011.10.012.
34. Mattheolabakis G, Wong CC, Sun Y, Amella CA, Richards R, Constan-tinides PP, Rigas B. 2014. Pegylation improves the pharmacokinetics and bioavailability of small-molecule drugs hydrolyzable by esterases: a study of phospho-ibuprofen. J Pharmacol Exp Ther 351:61–66. https://doi.org/10.1124/jpet.114.217208.
35. Harris JM, Chess RB. 2003. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2:214–221. https://doi.org/10.1038/nrd1033.
36. Gurjar M. 2015. Colistin for lung infection: an update. J Intensive Care 3:3. https://doi.org/10.1186/s40560-015-0072-9.
37. Falagas ME, Kasiakou SK. 2005. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 40:1333–1341. https://doi.org/10.1086/429323.
38. Cimerman N, Kosorok MD, Korant BD, Turk B, Turk V. 1996. Characterization of cystatin C from bovine parotid glands: cysteine proteinase inhibition and antiviral properties. Biol Chem Hoppe Seyler 377:19–23. https://doi.org/10.1515/bchm3.1996.377.1.19.
39. Björck L, Grubb A, Kjellén L. 1990. Cystatin C, a human proteinase inhibitor, blocks replication of herpes simplex virus. J Virol 64:941–943.
40. Kar S, Ukil A, Das PK. 2011. Cystatin cures visceral leishmaniasis by NF-B-mediated proinflammatory response through co-ordination of TLR/MyD88 signaling with p105-Tpl2-ERK pathway. Eur J Immunol 41: 116–127. https://doi.org/10.1002/eji.201040533.
41. Pyles RB, Jezek GE, Eaves-Pyles TD. 2010. Toll-like receptor 3 agonist protection against experimental Francisella tularensis respiratory tract infection. Infect Immun 78:1700 –1710. https://doi.org/10.1128/IAI.00736-09.
42. Coban AY. 2012. Rapid determination of methicillin resistance among Staphylococcus aureus clinical isolates by colorimetric methods. J Clin Microbiol 50:2191–2193. https://doi.org/10.1128/JCM.00471-12.